December 5 -- Lanzhou Foci Pharmaceutical (RCode:002644:), a company which researches, produces and sells Chinese patented drugs, plans to issue 20.20 million shares in its initial public offering on the Small and Medium-Sized Enterprises Board, reports ptw.net, citing a company filing.

After the completion of the offering, the company will have an enlarged share capital of 80.78 million shares.

Bookbuilding will take place from December 6-8, while subscription will be on December 13.

The company makes 10 types of medicines, including those in the form of tablets, syrups, oral solutions, granules, and capsules. It has the licenses to produce 462 types of drugs.

Proceeds raised will be used for the first phase of an expansion and technology upgrading program. The investment capital required is 245 million yuan.